News Category
Annovis Bio's three presentations at the 2026 CTAD conference will showcase buntanetap's mechanism, Phase 3 trial design, and AI-driven blood-brain ba...
NeuroThera Labs has completed manufacturing and obtained European QP batch release certification for its SCI-110 investigational drug, enabling shipme...
BioVersys announced peer-reviewed publications showing BV100 achieves high lung concentrations and has a manageable drug interaction profile, strength...
Quantum BioPharma's Unbuzzd alcohol recovery formulation gained mainstream attention through a Men's Fitness article, but the coverage highlights both...
NanoViricides reports positive juvenile animal safety results for its broad-spectrum antiviral NV-387, potentially enabling pediatric trials for Ebola...
Quantum BioPharma's Unbuzzd alcohol recovery formulation gained mainstream attention through a Men's Fitness article that highlighted promising but li...
Tonix Pharmaceuticals will present poster data on TONMYA for fibromyalgia at the 2026 IASP World Congress, highlighting the first new treatment approv...
Measles infections cause lasting immune vulnerabilities, making survivors susceptible to other infections, highlighting the need for increased vaccine...
Tonix Pharmaceuticals will present its TNX-801 vaccine platform at the World Vaccine Congress Europe, highlighting its potential to address mpox and o...
OrthodontiCell has secured funding to complete testing for its bioelectric technology that aims to accelerate orthodontic tooth movement, advancing to...
hyperCORE International has elected new officers to lead its strategic scaling platform, reinforcing its dual mission of accelerating growth for indep...
Quantum BioPharma's FDA clearance to begin Phase 2 testing of Lucid-MS marks a significant step for a non-immunological approach to multiple sclerosis...
The American Heart Association has selected five finalists for its 2026 Health Tech Competition, highlighting emerging technologies that could transfo...
NanoViricides has initiated a Phase IIA trial of its broad-spectrum antiviral NV-387 in oral gummy form for Ebola Bundibugyo virus, marking a signific...
Nutriband Inc. raised $1.75 million from warrant exercises to fund the clinical development and NDA submission for its abuse-deterrent fentanyl patch,...
Leksum's agreement with the Medical University of Vienna to prepare for Phase I/II trials of LK-ICU highlights a potential breakthrough for ICU-acquir...
Newron Pharmaceuticals is reviewing FDA feedback on a clinical hold at U.S. study centers for its Phase 3 ENIGMA-TRS 2 trial of evenamide, while enrol...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its novel Lucid-MS multiple sclerosis treatment into Phase 2 execu...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to implement a Phase 2 trial of Luc...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its neuroprotective Lucid-MS treatment into a Phase 2 trial, poten...
XORTX Therapeutics is advancing its gout treatment XORLO through clinical and manufacturing milestones, aiming for an FDA New Drug Application in abou...
Quantum BioPharma's study start-up agreement with Thermo Fisher's clinical research business marks a critical step toward launching a Phase 2 trial of...
NanoViricides will present at the NIBA 153rd Investment Conference, highlighting its broad-spectrum antiviral NV-387 now in Phase 2 trials for Ebola a...
Quantum BioPharma's study start-up agreement with Thermo Fisher for its Phase 2 Lucid-MS trial marks a critical step toward developing a first-in-clas...
India's drug regulator has cleared Okogen's EMERALD Phase 1/2 study of Treyegen (OKG-0303), a single ophthalmic therapy designed to treat both viral a...
NanoViricides' Phase II trial of NV-387 oral gummies for Ebola moves forward, potentially offering a deployable treatment for outbreaks in resource-li...
Nutriband Inc. celebrates five years on Nasdaq with a shareholder letter outlining milestones in its AVERSA Fentanyl patch development and upcoming re...
Gianluca Cerri, MD, a Louisiana emergency physician, is urging rural hospitals to adopt a personal policy of discussing medication-assisted treatment ...
Incannex Healthcare has transitioned its IHL-42X program into active clinical execution with the DReAMzz trial now dosing patients, a critical step to...
AAG Zacheriel's debut novel, The Vena Protocol: First Blood, uses fiction to highlight the critical importance of integrity in clinical trials and the...
Quantum BioPharma's Lucid-MS moves to Phase 2 in multiple sclerosis, while its unbuzzd(TM) investment offers a 7% royalty stream up to $250 million.
Quantum BioPharma's Lucid-MS moves to Phase 2 for multiple sclerosis, while the company holds a 7% royalty on unbuzzd sales up to $250 million.
A new NFID survey shows widespread support for vaccines but significant gaps in knowledge and access, highlighting opportunities to increase uptake an...
NanoViricides has received regulatory approval for Phase II trials of its broad-spectrum antiviral NV-387 in the Democratic Republic of Congo and obta...
NanoViricides has begun patient enrollment and dosing in a Phase II trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus in the Democratic Republic ...
The FDA's approval of Quantum BioPharma's IND for Lucid-MS allows the company to begin Phase 2 testing of its novel multiple sclerosis treatment, pote...
Nutriband Inc. appoints former Navy SEAL Robert J. O’Neill to its Advisory Board, bringing strategic and operational expertise as the company advances...
Creative Biolabs has launched a comprehensive suite of therapeutic antibody engineering services aimed at helping researchers overcome common preclini...
FamiCord AG's CDMO division will manufacture VERIGRAFT's personalized tissue-engineered vein for a pivotal Phase II/III trial, expanding its advanced ...
Quantum BioPharma (NASDAQ: QNTM) has received FDA approval for its Investigational New Drug application for Lucid-MS, allowing the company to begin ph...
In vitro ADME studies are critical for early assessment of drug candidates, and Creative Bioarray offers comprehensive services to help pharmaceutical...
A new study reveals that the risk of sepsis, meningitis, or pneumonia from air pollution depends on individual bacterial strains, highlighting the nee...
Peptide Wholesale Supply has extended its HPLC peptide testing and batch documentation protocols to bulk orders of BPC-157, Semaglutide, and Tirzepati...
Patients with small cell lung cancer should ask about clinical trials at their first appointment because timing can determine access to promising new ...
GeoVax's agreement with CEPI to use the Centralised Laboratory Network for its GEO-MVA Phase 3 trial aims to generate independent, standardized data t...
Tevard Biosciences' preclinical research demonstrates that engineered suppressor tRNAs can restore full-length dystrophin and improve muscle function ...
Creative Biolabs has broadened its lipid-based delivery development services to help researchers engineer customized, functionalized liposomes that ad...
BioCorRx Inc. has appointed Richard J. Baum, former Acting Director of the White House Office of National Drug Control Policy, to its Strategic Adviso...
